Royal Bank of Canada Cuts Bausch Health Companies (NYSE:BHC) Price Target to $8.50

Bausch Health Companies (NYSE:BHC - Get Free Report) had its price target cut by Royal Bank of Canada from $9.00 to $8.50 in a report issued on Monday,BayStreet.CA reports. The firm currently has a "sector perform" rating on the stock. Royal Bank of Canada's price target would indicate a potential upside of 96.53% from the stock's current price.

Separately, Jefferies Financial Group reiterated a "hold" rating and issued a $8.00 price objective (down previously from $12.00) on shares of Bausch Health Companies in a report on Thursday, February 6th. One investment analyst has rated the stock with a sell rating, six have given a hold rating and one has assigned a buy rating to the company. According to data from MarketBeat.com, Bausch Health Companies presently has an average rating of "Hold" and a consensus price target of $7.17.

Bausch Health Companies Stock Down 1.0 %

Shares of NYSE:BHC traded down $0.05 on Monday, hitting $4.33. The company had a trading volume of 2,276,584 shares, compared to its average volume of 2,693,855. The firm's 50-day simple moving average is $6.53 and its two-hundred day simple moving average is $7.54. The firm has a market capitalization of $1.59 billion, a price-to-earnings ratio of -36.04, a P/E/G ratio of 0.37 and a beta of 0.43. Bausch Health Companies has a 1 year low of $3.96 and a 1 year high of $9.85.

Remove Ads

Bausch Health Companies (NYSE:BHC - Get Free Report) last issued its quarterly earnings data on Wednesday, February 19th. The company reported $1.21 EPS for the quarter, missing the consensus estimate of $1.65 by ($0.44). Bausch Health Companies had a negative return on equity of 577.82% and a negative net margin of 0.48%. The company had revenue of $2.56 billion during the quarter, compared to analysts' expectations of $2.51 billion. Equities research analysts anticipate that Bausch Health Companies will post 4.41 EPS for the current year.

Hedge Funds Weigh In On Bausch Health Companies

Several large investors have recently modified their holdings of BHC. Mountain Hill Investment Partners Corp. purchased a new position in Bausch Health Companies in the fourth quarter worth about $56,000. Bank of Nova Scotia purchased a new position in Bausch Health Companies in the 4th quarter worth approximately $83,000. One68 Global Capital LLC bought a new position in Bausch Health Companies in the 4th quarter valued at approximately $90,000. Balyasny Asset Management L.P. purchased a new stake in Bausch Health Companies during the 4th quarter valued at $97,000. Finally, Alpine Global Management LLC bought a new stake in shares of Bausch Health Companies in the 4th quarter worth $114,000. Hedge funds and other institutional investors own 78.65% of the company's stock.

Bausch Health Companies Company Profile

Bausch Health Companies Inc operates as a diversified specialty pharmaceutical and medical device company in the United States and internationally. It develops, manufactures, and markets a range of products primarily in gastroenterology, hepatology, neurology, dermatology, international pharmaceuticals, over-the-counter (OTC) products, aesthetic medical devices, and eye health.